# Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

Study · id `cardio:ct-nct03219320` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03219320](<https://clinicaltrials.gov/study/NCT03219320>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03219320

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 301 participants.

## Technical summary

Registry record NCT03219320. Randomized; triple masking; primary purpose supportive care. Start 2017-06-27 (actual); primary completion 2018-11-02 (actual). Results posted on 2020-06-09.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose supportive care
- Phase: Phase 2
- Enrolled: 301 participants (enrolled count; ClinicalTrials.gov record NCT03219320, source copy `cardio:ctgov-nct03219320-2020-06-09`, retrieved 2026-10-26)
- Started: 2017-06-27 (actual) (ClinicalTrials.gov record NCT03219320, source copy `cardio:ctgov-nct03219320-2020-06-09`, retrieved 2026-10-26)
- Primary completion: 2018-11-02 (actual) (ClinicalTrials.gov record NCT03219320, source copy `cardio:ctgov-nct03219320-2020-06-09`, retrieved 2026-10-26)
- Completion: 2018-11-02 (actual) (ClinicalTrials.gov record NCT03219320, source copy `cardio:ctgov-nct03219320-2020-06-09`, retrieved 2026-10-26)
- Results first posted: 2020-06-09 (ClinicalTrials.gov record NCT03219320, source copy `cardio:ctgov-nct03219320-2020-06-09`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT03219320, source copy `cardio:ctgov-nct03219320-2020-06-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03219320-2020-06-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
- Acronym: DPN
- Condition: Diabetic Peripheral Neuropathy
- Intervention (Drug): NYX-2925
- Intervention (Drug): Placebo
- Lead sponsor: Aptinyx
- Lead sponsor class: INDUSTRY
- Collaborator: Syneos Health
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as a collaborator: Syneos Health (`cardio:org-syneos-health`)

## Provenance

Content hash: f2c9ed338911f79321a32144998efceed2113ac2be23f1a678f738cf016b67d1
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
